Filterable News List

New York, NY - September 15, 2026 - Critical Metals Corp. (Nasdaq: CRML) provided an update on its proposed acquisition of European Lithium Limited (ASX: EUR, FRA: PF8, OTC: EULIF) following a favorable court ruling in Australia.

Court Orders and Scheme Meetings

The Supreme Court of Western Australia has granted orders directing European Lithium to convene meetings of its shareholders and optionholders to vote on the proposed schemes of arrangement. The Scheme Booklet has also been registered with the Australian Securities and Investments Commission (ASIC).

Transaction Details

• Acquisition of 100 percent of European Lithium's issued share capital and listed options.
• Consideration to be satisfied by issuing new ordinary shares in Critical Metals Corp.
• Scheme meetings scheduled for Thursday, October 22, 2026, in West Leederville, Western Australia.
• Implementation of the schemes is expected in November 2026, pending securityholder and court approvals.

New York, NY, USA - Market Technology Acquisition Corp (Nasdaq: MTAKU) announced that starting September 17, 2026, holders of the units sold in its initial public offering may elect to separately trade the Class A ordinary shares and warrants included in the units.The separated Class A ordinary shares and warrants will trade on the Nasdaq…

… Read on — Pro Members

La Jolla, California, USA - Three Lions Acquisition Corp. announced that, commencing on or about September 17, 2026, holders of the units sold in its initial public offering may elect to separately trade the ordinary shares and warrants included in the units.The separated ordinary shares and warrants are expected to trade on the Nasdaq Global…

… Read on — Pro Members

Santa Monica, California, USA - Catalyst Acquisition Corp. (Nasdaq: CATLU) announced that, commencing September 17, 2026, holders of the units sold in its initial public offering may elect to separately trade the Class A ordinary shares and rights included in the units.The separated Class A ordinary shares and rights will trade on the Nasdaq Stock…

… Read on — Pro Members

Hong Kong, HK -- Tianci International, Inc. (NASDAQ: CIIT) announced that it has entered into a Memorandum of Understanding on Strategic Cooperation with BTC Digital Ltd. (NASDAQ: BTCT) for an approximately 3 MW crypto computing project, initiating the phased advancement of the initiative.

The project builds upon a prior strategic cooperation memorandum signed on October 14, 2025, and existing mining-equipment hosting arrangements between the companies. Under the new agreement, CIIT plans to deploy crypto computing equipment in phases to reach an aggregate electrical load of approximately 3 MW within twelve months. BTCT will provide infrastructure and operational support, including sites, power, and equipment deployment.

Transaction Details

• CIIT targets an aggregate electrical load of approximately 3 MW within twelve months.
• BTCT provides sites, power, hosting infrastructure, and operational support.
• CIIT handles equipment procurement, project funding, transportation, insurance, and permits.
• The non-binding MOU has a twelve-month term and allows for separate definitive agreements.

Irvine, California, USA - Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in advanced diabetes management solutions, announced the U.S. Food and Drug Administration (FDA) clearance of Mint, its new patch pump featuring a transformative reusable and disposable architecture. Additionally, the company unveiled 3D Intelligence, its next-generation insulin dosing algorithm, which has been submitted to the FDA via a 510(k) application.

The Mint patch pump does not require recharging, integrates with industry-leading continuous glucose monitors, and enables smartphone control for both iOS and Android users. The full commercial launch in the United States is anticipated to begin in the first quarter of 2027, with expected manufacturing capacity to produce at least 1.5 million disposable units during 2027.

The newly unveiled 3D Intelligence algorithm is designed to offer clinicians three selectable experiences: Original, Optimized, and Conservative. Subject to regulatory clearance, the algorithm is expected to power both iLet 3D and Mint 3D platforms, maximizing user choice in hardware and treatment approach.

Key Highlights

• FDA clearance received for the Mint patch pump architecture.
• Full U.S. commercialization expected in Q1 2027.
• 3D Intelligence algorithm submitted to the FDA through a 510(k) application.
• Updated full year 2026 revenue guidance estimated at approximately $121 million to $126 million.

SAN DIEGO, September 15, 2026 -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company, announced updated clinical data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations, such as EGFR C797S. The data were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer in Seoul, South Korea.

BH-30643 is an investigational, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor. In patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, the treatment demonstrated significant anti-tumor activity and a favorable safety profile.

Key Highlights

• In 40 patients with EGFR C797S-positive resistance, BH-30643 demonstrated an objective response rate of 45% and a disease control rate of 88%.
• At the time of efficacy follow-up, 63% of patients remained on treatment with a median follow-up of 6.9 months.
• Patients had received a median of two prior lines of therapy, including prior osimertinib, chemotherapy, antibody-drug conjugates, and a history of brain metastases.
• Treatment-related dose reductions and discontinuations were low at 9% and 3%, respectively, among patients treated at expansion doses.

Dayton, MN, USA - Forgent Power Solutions, Inc. (NYSE: FPS), a leading designer and manufacturer of electrical distribution equipment, announced its financial results for the fiscal fourth quarter and full year ended June 30, 2026, exceeding the high end of its guidance.

During the fourth quarter, Forgent achieved revenues of $462 million, marking a 94 percent increase year-over-year. The company reported a net income of $66 million and an Adjusted EBITDA of $113 million, up 163 percent from the prior year. Bookings reached a record $1,503 million, driving the all-time high backlog to $3.0 billion.

For the full fiscal year 2026, revenues totaled $1,420 million with a net income of $106 million and Adjusted EBITDA of $323 million. The company also issued robust guidance for fiscal year 2027, projecting revenues between $2,400 million and $2,600 million.

Financial Highlights

• Q4 Revenues: $462 million (up 94% year-over-year)
• Q4 Net Income: $66 million
• Q4 Adjusted EBITDA: $113 million (up 163% year-over-year)
• Full Year 2026 Revenues: $1,420 million (up 89% year-over-year)

PORTLAND, Maine, USA - The Elmet Group Co. (NASDAQ: ELMT) announced plans to allocate capital from a $450 million committed investment by the United States Department of War to establish a secure, vertically integrated tungsten supply chain, expand domestic manufacturing, and strengthen critical mineral sources.

The strategic funding will support several transformative initiatives across Elmet's global operations, including facility modernization, new joint ventures, and international partnerships to secure long-term access to raw materials and processing capabilities.

Key Highlights

• Domestic Infrastructure: Over $165 million will modernize and expand existing facilities in Lewiston, Maine; Coldwater, Michigan; and Euclid, Ohio.
• Springer Tungsten Complex: Approximately $150 million will be allocated to the Imlay, Nevada complex operated by Blue Moon Metals, creating a majority-owned joint venture with Blue Moon and EQ Resources to restart ammonium paratungstate conversion.
• Allied Supply Network: Up to $150 million will support international partnerships, including the Mt. Carbine Mine in Australia and the Barruecopardo Mine in Spain, to diversify supply.
• New Division: Elmet is launching Elmet Refining & Trading to coordinate global sourcing, processing, and delivery.

PITTSBURGH, PA, USA - Eos Energy Enterprises, Inc. (NASDAQ: EOSE) announced that it has received an $87 million first advance under the second tranche of its loan agreement with the U.S. Department of Energy's Office of Energy Dominance Financing. The advance reimburses 80% of eligible costs for the company's Thorn Hill manufacturing facility in Warrendale, Pennsylvania, bringing total draws under the DOE facility to approximately $178 million since 2024.

Line 2 entered commercial production in June 2026 and is currently ramping toward its designed annual manufacturing capacity of approximately 2 GWh. With the planned relocation of Line 1 to Thorn Hill, Eos expects the facility to support around 4 GWh of annual manufacturing capacity across two lines.

Transaction Details

• Advance amount: $87 million under the second tranche
• Total DOE facility draws: Approximately $178 million
• Reimbursement rate: 80% of eligible costs for the Thorn Hill facility
• Capacity target: 4 GWh of annual manufacturing capacity across two lines